British journal of haematology
-
Randomized Controlled Trial Multicenter Study Comparative Study
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most patients relapse after ASCT. We investigated in a randomised phase II study the outcome of a chemo-immuno regimen and ASCT with or without maintenance therapy with bortezomib. ⋯ Patients with bortezomib maintenance had a 5-year EFS of 63% (95% CI 44-78%) and 5-year OS of 90% (95% CI 72-97%). The patients randomised to observation had 5-year PFS of 60% (95% CI, 40-75%) and OS of 90% (95% CI 72-97%). In conclusion, in this phase II study we found no indication of a positive effect of bortezomib maintenance after ASCT.
-
Letter Multicenter Study Clinical Trial
ABO phenotype and death in critically ill patients with COVID-19.
-
Letter Multicenter Study Clinical Trial
Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series.
-
Letter Case Reports
Efficacy of therapeutic plasma exchange in severe COVID-19 patients.